Nasdaq · Healthcare
CHAMPIONS ONCOLOGY, INC. (CSBR)
As-reported financials and recent SEC filings for CHAMPIONS ONCOLOGY, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$56.9M
Net income
$4.7M
Net margin
8.3%
Diluted EPS
$0.33
ROE
124.6%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $56.9M | $50.2M | $53.9M | $49.1M | $41.0M |
| Gross profit | $28.6M | $20.8M | $24.3M | $25.5M | $19.6M |
| Operating income | $4.6M | $-7.4M | $-5.3M | $607,000 | $366,000 |
| Net income | $4.7M | $-7.3M | $-5.3M | $548,000 | $362,000 |
| Diluted EPS | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-03-30
View on EDGAR →10-Q2026-03-12
View on EDGAR →8-K2026-03-12
View on EDGAR →42026-01-30
View on EDGAR →42026-01-30
View on EDGAR →32026-01-16
View on EDGAR →10-Q2025-12-15
View on EDGAR →8-K2025-12-15
View on EDGAR →Largest Healthcare peers
Go deeper on CSBR
Search CHAMPIONS ONCOLOGY, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.